Results 1 to 10 of about 72,228 (243)
Immunological Medicine, 2023 Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons.
Hideto Kameda
doaj +3 more sources
JAK inhibitors in rheumatology
Immunological Medicine, 2023 Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field.
Kunihiro Yamaoka, Kenji Oku
doaj +3 more sources
Journal for ImmunoTherapy of Cancer, 2022 During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Gabriel Levy +3 more
doaj +6 more sources
JAK Inhibitors in Psoriatic Disease
Clinical, Cosmetic and Investigational Dermatology, 2023 Matteo Megna,1 Luca Potestio,1 Angelo Ruggiero,1 Sara Cacciapuoti,1 Francesco Maione,2 Marco Tasso,3 Francesco Caso,3,* Luisa Costa3,* 1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples,
Megna M +7 more
doaj +4 more sources
JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease [PDF]
Therapeutic Advances in GastroenterologyExtra-intestinal manifestations (EIMs) commonly occur in patients with inflammatory bowel diseases (IBD) and contribute significantly to morbidity and reduced quality of life. Their management remains challenging.
Fotios S. Fousekis +4 more
doaj +2 more sources
JAK1-selective inhibitors versus pan-JAK inhibitors: comparative real-world study of drug retention in chronic inflammatory arthritis [PDF]
Therapeutic Advances in Musculoskeletal DiseaseBackground: Janus kinase inhibitors (JAKi) are effective treatments for chronic inflammatory arthritis (CIA). Tofacitinib and baricitinib are pan-JAK inhibitors, while upadacitinib and filgotinib are JAK1-selective inhibitors. Objective: This study aimed
Leticia Leon +7 more
doaj +2 more sources
Indian Journal of Dermatology, Venereology and Leprology, 2023 The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri +1 more
openaire +2 more sources
Janus kinase inhibitors in autoimmune bullous diseases
Frontiers in Immunology, 2023 Autoimmune bullous disease (AIBD) is a severe skin disorder caused by autoantibodies that target intercellular or cell-matrix adhesion proteins.
Dawei Huang +9 more
doaj +1 more source
JAK Inhibitors in Rheumatoid Arthritis
European Medical Journal Allergy & Immunology, 2022 JAK inhibitors (JAKi) are targeted, small-molecule, disease-modifying therapies that are the newest class of treatments to emerge for the management of rheumatoid arthritis (RA) and the first oral disease-modifying anti-rheumatic drugs (DMARD) to ...
Kathryn Biddle +2 more
doaj +1 more source
Journal of Allergy and Clinical Immunology, 2021 Asthma is an inflammatory disease of the airways characterized by intermittent episodes of wheezing, chest tightness, and cough. Many of the inflammatory pathways implicated in asthma involve cytokines and growth factors that activate Janus kinases (JAKs).
Steve N, Georas +3 more
openaire +3 more sources